Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Blood|May 13, 2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 studyDonna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
The Journal of Experimental Medicine|May 4, 2005
Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patientsDavid H Chang, Keren Osman, John Connolly, et al.
Blood|September 10, 2014
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosisDonna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Cancer Journal|August 18, 2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research GroupAndrea Havasi, Cihan Heybeli, Nelson Leung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide MaintenanceMeighan Palazzo, Gunjan L Shah, Olivia Copelan, et al.
Blood Neoplasia|July 12, 2026
CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Pageof 8